Results 101 to 110 of about 470,990 (120)
Some of the next articles are maybe not open access.
Clinical Lymphoma Myeloma and Leukemia, 2022
Mycosis fungoides (MF), the most common subtype of Cutaneous T-cell lymphomas, is caused by malignant T-cell proliferations in the skin that can invade blood, lymph nodes, or viscera. Currently, data on efficacy of maintenance therapies in MF are lacking.
Emily Correia +7 more
openaire +2 more sources
Mycosis fungoides (MF), the most common subtype of Cutaneous T-cell lymphomas, is caused by malignant T-cell proliferations in the skin that can invade blood, lymph nodes, or viscera. Currently, data on efficacy of maintenance therapies in MF are lacking.
Emily Correia +7 more
openaire +2 more sources
Chlormethine Gel for the Treatment of Mycosis Fungoides (Cutaneous T-cell Lymphoma) in Canada.
Skin therapy letter, 2023Mycosis fungoides (MF) is the most common type of cutaneous T-cell lymphoma (CTCL), representing almost 50% of all lymphomas arising in the skin. There is an unmet need in the treatment of MF in Canada, as current available therapies for early-stage MF are limited, without topical agents previously indicated.
Robert, Gniadecki, Emilia, Paron
openaire +1 more source
Chlormethine gel as maintenance treatment for patients with mycosis fungoides
European Journal of Cancer, 2023Larisa Geskin +7 more
openaire +1 more source
Chlormethine gel in combination with retinoids for treatment of mycosis fungoides
European Journal of Cancer, 2023Miriam Teoli +3 more
openaire +1 more source
Real-life evaluation of efficacy and tolerability of chlormethine gel in Italian centers
European Journal of Cancer, 2022S Alberti-Violetti +7 more
openaire +1 more source
Chlormethine gel as first-line and as maintenance treatment in MF stages IA–IIB
European Journal of Cancer, 2023Marios Koumourtzis +9 more
openaire +1 more source
ESDR134 - Percutaneous Absorption of Chlormethine Gel in Human Skin: In Vitro Permeation Testing
2021openaire +1 more source